B
BIO
vs
W
WIG20
Over the past 12 months, BIO has underperformed WIG20, delivering a return of +18% compared to the WIG20's +33% growth.
Stocks Performance
BIO vs WIG20
Performance Gap
BIO vs WIG20
Performance By Year
BIO vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Bioton SA
Glance View
BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
